Abstract

Intervertebral disc (IVD) degeneration causes low-back pain through disc compression, prolapse and herniation. Inflammation of the IVD and subsequent degeneration produce altered glycosylation profiles in several animal models of IVD injury and ageing, although the function of this altered glycosylation pattern in humans is unknown. Altered N-glycome, specifically sialylated and fucosylated N-glycosylation motif expression, might play a role in inflammation and disease progression. Healthy (foetal and adolescent idiopathic scoliosis) and degenerated (lumbar degeneration) human IVD glycosylation patterns were studied using lectin histochemistry. Small-molecule fluorinated sugar analogues (3Fax-Peracetyl Neu5Ac; 2F-Peracetyl-Fucose) were used to inhibit sialylation and fucosylation in an in vitro model of inflammation, to investigate their effects on the glycosignature, cell metabolism, extracellular matrix synthesis and cell migration. The effects of interleukin (IL)-1β, tumour necrosis factor (TNF)-α and IL-6 on glycosylation in human nucleus pulposus cells were investigated by lectin histochemistry, PCR and enzyme-linked immunosorbent assay (ELISA). In the in vitro model of IVD degeneration, cytokine-induced inflammation-induced hypersialylation was observed, as indicated by Sambucus nigra I binding. However, this modification was inhibited by the sialyltransferase inhibitor. Inhibition of sialylation and fucosylation modulates cell migration and protein translation of catabolic enzymes in response to inflammation. The altered patterns of glycosylation in human tissue in degeneration was consistent with previous IVD studies in murine, bovine and ovine models. The present study was the first functional investigation of glycosylation in human degenerated IVD, elucidating the role of the glycome in disease progression and identified potential therapeutic targets for future regenerative therapies.

Keywords: Glycosylation, inflammation, intervertebral disc, degeneration.

*Address for correspondence: Prof Abhay Pandit, CÚRAM, SFI Research Centre for Medical Devices, National University of Ireland, Galway, Ireland.
Email: abhay.pandit@nuigalway.ie

Copyright policy: This article is distributed in accordance with Creative Commons Attribution Licence (http://creativecommons.org/licenses/by-sa/4.0/).

---

List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAL</td>
<td>Aleuria aurantia lectin</td>
</tr>
<tr>
<td>ACAN</td>
<td>aggrecan</td>
</tr>
<tr>
<td>ADAMTS-4</td>
<td>ADAM metallopeptidase with thrombospondin type 1 motif 4</td>
</tr>
<tr>
<td>AF</td>
<td>annulus fibrosus</td>
</tr>
<tr>
<td>AIS</td>
<td>adolescent idiopathic scoliosis</td>
</tr>
<tr>
<td>ATP</td>
<td>adenosine triphosphate</td>
</tr>
<tr>
<td>BCA</td>
<td>bicinchoninic acid</td>
</tr>
<tr>
<td>BSA</td>
<td>bovine serum albumin</td>
</tr>
<tr>
<td>CD</td>
<td>cluster of differentiation</td>
</tr>
<tr>
<td>CMP</td>
<td>cytidine-5’-monophosphate</td>
</tr>
<tr>
<td>COL1</td>
<td>collagen type 1</td>
</tr>
<tr>
<td>COL2</td>
<td>collagen type 2</td>
</tr>
<tr>
<td>Con A</td>
<td>concanavalin A</td>
</tr>
<tr>
<td>DAPI</td>
<td>4,6-diamidino-2-phenylindole</td>
</tr>
<tr>
<td>DSA</td>
<td>Datura stramonium agglutinin</td>
</tr>
<tr>
<td>ECAR</td>
<td>extracellular acidification rate</td>
</tr>
<tr>
<td>ECM</td>
<td>extracellular matrix</td>
</tr>
</tbody>
</table>
Introduction

IVD degeneration is a significant cause of low-back pain through disc compression, prolapse and herniation (Zheng and Chen, 2015). Inflammation of the IVD and its subsequent degeneration produce altered glycosylation profiles in several animal models of IVD injury and ageing, although the function of this altered glycosylation pattern in humans is unknown. Many cellular processes are altered in IVD degeneration. Factors such as cellular nutrition, pH, oxygen tension and altered mechano-sensing cause the differential regulation of cellular pathways towards a pro-inflammatory, senescent phenotype (Adams et al., 2009; 2015). This is further characterised by reduced ECM synthesis, upregulation of catabolic enzymes and increased apoptotic signalling (Buckwalter, 1995).

Glycosylation of glycoproteins contributes to the functional diversity required to generate extensive variation in activity and regulation of cellular pathways (Paulson and Colley, 1989). Glycosylation mediates critical processes such as protein synthesis (Komekado et al., 2007), receptor expression and activity (Da Silva Correia and Ulevitch, 2002; Liu et al., 2011) as well as enzyme functions (Kim and Varčič, 1997).

Glycans are post-translational modifications coded by over 500 genes, present on the peptide backbone of glycoproteins in N- and O-linked conjugations. Glycan synthesis starts on the rough ER in a non-template driven process coordinated by glycosyltransferases and glycohydrolases. Many glycosyltransferases exist and some are tissue-specific (Raman et al., 2005). In the ER, glycosyltransferases add monosaccharide residues to the glycan core, which is refined in the GA. Sialylated glycans play a crucial role in cell-to-cell interactions, cell signalling, migration and development (Bhide and Colley, 2017; Chen and Varčič, 2010; Natoni et al., 2019). STs are part of the glycosyltransferase enzyme family that play an integral role in the biosynthesis of sialylated glycans and carbohydrate-containing moieties. STs are bound to the GA by a transmembrane anchor, orientated with the active site towards the lumen (Li and Chen, 2012). Sialic acid may be α-(2,3/6/8)-conjugated to galactose. Sialic acid linkage is modulated by the NF-κB pathway, upregulating ST6Gal I mRNA over ST3GalNAc IV mRNA expression specifically, favouring α-(2,6) over α-(2,3) expression (Higai et al., 2006). α-(2,6)-sialylation is crucial for osteoclast differentiation (Takahata et al., 2007).

Fucose is another essential glycan residue expressed on the cell surface, playing an essential role in various biological processes including tissue development, angiogenesis, selectin-mediated cell adhesion, leukocyte localisation, inflammation, self-recognition and cell-to-cell interactions (Becker and Lowe, 2003). α-(1,2) fucosylation, regulated by two fucosyltransferase-coding genes, FUT1 and FUT2, is responsible for H- and Lewis X antigens (Kyprianou et al., 1990). α-(1,3/4) fucosylation is present in glycosylation motifs such as Lewis X/sialyl-Lewis X and is governed by FUT3-7 (Henry et al., 1995; Legault et al., 1995). Finally, α-(1,6) fucosylation, is widely expressed in mammalian...
The role of glycosylation in IVD degeneration

K Joyce et al.

The role of glycosylation in IVD degeneration. Orthop Proc 100-B. DOI: 10.1302/1358-992X.2018.16.117; conference abstract]. TNF-α, a pro-inflammatory cytokine, increases the expression of sialyltransferase (ST3Gal-III/IV) and FUT3/4 – to increase sialylation and fucosylation, respectively – as well as of sialyl-Lewis X epitope in human bronchial mucosa (Watanabe et al., 2004). IL-6 and IL-8 also increase the expression of glycosyltransferases (FUT3/11 and ST3Gal2/6) and sulphotransferases (carbohydrate sulphotransferase four genes) in bronchial mucosa (Groux-Degroote et al., 2008). IL-1β and TNF-α upregulate the expression of α-(2,3) sialyltransferases in primary human chondrocytes in vitro on both N- and O-glycans (Pabst et al., 2010). The shift toward α-(2,3) sialylation increases the population of complex-type N-glycans. TNF-α decreases the expression of core fucosylation in primary human chondrocytes (Pabst et al., 2010). It is unknown what role the glyome plays in modulating the cellular microenvironment and response to the noxious environment of the degenerated IVD.

3Fax-Peracetyl Neu5Ac (Neu5Ac-inhib) is an ideal candidate molecule to inhibit sialyltransferase enzymes to assess the downstream effects of glycosylation inhibition (Rillahan et al., 2012). Neu5Ac-inhib is a fluorinated analogue of sialic acid, which is readily taken into cells by diffusion and converted into a corresponding donor substrate analogue of CMP-Neu5Ac. Although it closely resembles the natural CMP-sialic acid substrate, this fluorinated derivative destabilises the oxocarbenium transition state needed for Neu5Ac transfer to galactose residues (Montgomery et al., 2016). The accumulation of this fluorinated CMP-Neu5Ac analogue also inhibits de novo synthesis of CMP-Neu5Ac through a negative feedback loop (Hinderlich et al., 2015). Competitive inhibition of the sialyltransferase enzyme is a novel approach to glycosylation inhibition to elucidate the role of sialylation in IVD degeneration. An equivalent molecule, 2F-Peracetyl-Fucose (fucose-inhib), inhibits fucosyltransferases non-specifically to block de novo fucosylation (Rillahan et al., 2012).

It was hypothesised that glycosylation plays a role in the degeneration cascade in the IVD and targeted inhibition of sialylation and fucosylation may modulate the glycomic response to inhibit or dampen cytokine-mediated signalling in NP cells. The present study evaluated the phenotype of glycosignature of healthy and degenerated human NP and established an in vitro model of IVD degeneration in NP cells by cytokine-induced inflammation, demonstrating the aberrant expression of sialylation and fucosylation.

The effects of glycosylation inhibitors on sialylation and fucosylation expression were investigated in human NP cells in an inflammatory environment to assess the efficacy of targeting aberrations in the glycosylation profile. Glycosylation inhibitors, Neu5Ac-inhib and Fucose-inhib, efficiently inhibited the hypersialylation and hyperfucosylation observed in the cytokine-induced inflammatory model without any negative impact on cell survival. This inhibition restored glycosylation to physiological levels, which affected cell protein synthesis, inflammatory response, cell migration and respiration. To the authors’ knowledge, this is the first study to demonstrate the ability of glycosylation inhibitors to restore physiological glycosylation in human NP cells and to demonstrate the role of glycosylation in degeneration. This may offer new molecular targets for biomaterial functionalisation in the future.

Materials and Methods

Materials and reagents
3Fax-Peracetyl Neu5Ac and 2F-Peracetyl-Fucose were purchased from Merck. 96-well glass coverslip microplates were purchased from Ibidi. All lectins were purchased from Vector Labs. Human recombinant IL-1β, IL-6 and TNF-α were purchased from Peprotech. RNase inhibitor was purchased from Bioline. PCR primers were purchased from Eurofins. Human MMP-13 ELISA kit was purchased from Abcam. Teflon™ tape, Live/Dead® staining kit, alamarBlue® assay, DAPI, TaqMan® VIC®-labelled GAPDH primer and TaqMan® Universal PCR Master Mix, no AmpErase® UNG were purchased from Fisher Scientific. Primocin was purchased from InvivoGen. TaqMan FAM™ labelled COL1/2 primers were purchased from Thermo Fisher Scientific. All other materials and reagents were purchased from Sigma-Aldrich unless otherwise stated.

Human IVD tissue collection and preparation for lectin histochemistry

Discs from foetal and degenerated tissue were obtained from Utrecht University, the Netherlands. Collection of IVD specimens was performed according to the medical ethical regulations (protocol 12-364) of the University Medical Centre Utrecht (Utrecht, the Netherlands). Isolated discs were fixed in 10 % formalin for 48 h, decalcification of the vertebral bones was performed at 4 °C using ‘Kristensen’s decalcifying solution containing 18 % (v/v) formic acid and 3.5 % (w/v) sodium formate. Then, tissue samples were washed with tap water overnight and soaked (how long?) at 4 °C in a 20 % (w/v) sucrose solution until they were submerged in...
Table 1. Optimisation of glycosylation inhibition. 3Fax-Peracetyl Neu5Ac- and 2F-Peracetyl-Fucose-treated cells were cultured at various concentrations for 10 d.

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>3Fax-Peracetyl Neu5Ac (sialylation)</th>
<th>2F-Peracetyl Fucose (fucosylation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentration of inhibitor</td>
<td>50 µmol/L</td>
<td>50 µmol/L</td>
</tr>
<tr>
<td></td>
<td>300 µmol/L</td>
<td>300 µmol/L</td>
</tr>
<tr>
<td></td>
<td>500 µmol/L</td>
<td>500 µmol/L</td>
</tr>
</tbody>
</table>

Table 2. Lectin binding specificity and associated haptenic controls. Haptenic sugar is a monosaccharide/disaccharide that is pre-incubated with the lectin to cause non-competitive inhibition, to investigate the non-site-specific binding of the lectin as a control. Haptenic sugar is applied during optimisation to ensure no non-specific binding of the lectin to the sample. Abbreviations: GalNAc, N-acetyl glucosamine.

<table>
<thead>
<tr>
<th>Lectin</th>
<th>Binding specificity</th>
<th>Haptenic sugar (100 mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNA-I (Sambucus nigra I)</td>
<td>α-2,6 sialylation</td>
<td>Lactose</td>
</tr>
<tr>
<td>MAA-II (Maackia amurensis II)</td>
<td>α-2,3 sialylation</td>
<td>Lactose</td>
</tr>
<tr>
<td>AAL (Aleuria aurantia)</td>
<td>α-1,6 fucose</td>
<td>Fucose</td>
</tr>
<tr>
<td>UEA-I (Ullex europaeus agglutinin I)</td>
<td>α-1,2/3 fucose</td>
<td>Fucose</td>
</tr>
<tr>
<td>WGA (wheat germ agglutinin)</td>
<td>α-2,3/6 sialylation, GlcNAc</td>
<td>GlcNAc</td>
</tr>
<tr>
<td>PNA (peanut agglutinin)</td>
<td>β-1,3 galactosylation</td>
<td>Galactose</td>
</tr>
<tr>
<td>GS-I-B4 (Griffonia simplicifolia isolectin)</td>
<td>Terminal α-linked galactosylation</td>
<td>Galactose</td>
</tr>
<tr>
<td>Con A (concanavalin A)</td>
<td>α-linked mannosylation, glucosamine and GlcNAc</td>
<td>Mannose</td>
</tr>
</tbody>
</table>

Table 3. Primers utilised in the qRT-PCR analysis.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
<th>Base pairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collagen I</td>
<td>5’ GATTCCCTGGACCTAAAGGTTGC 3’</td>
<td>5’ AGCCCTCTCCATTTGCCAGCA 3’</td>
<td>19</td>
</tr>
<tr>
<td>Collagen II</td>
<td>5’ CCTGGCAAAGATGGTGAGACAG 3’</td>
<td>5’ CCTGTTTTTCCACCTACCTG 3’</td>
<td>19</td>
</tr>
<tr>
<td>18S</td>
<td>5’ GTCTCCTCTGACTTCAACACGGC 3’</td>
<td>5’ ACCACCCCTGTTGCTAGCCAA 3’</td>
<td>19</td>
</tr>
</tbody>
</table>

it. Tissues were embedded in OCT compound, snap-frozen in an isopentane bath cooled by liquid nitrogen and stored at −80 °C until sectioning at 10 µm using a cryostat (Leica CM1850).

Lectin staining

Lectin staining was performed as previously described (Mohd Isa et al., 2018). Briefly, the staining was carried out at room temperature. Tissue sections were initially washed in TBS-T (TBS with 0.05 % Triton X-100). TBS is an isotonic, non-toxic pH-stabilising solution used for membrane washing. Triton X is used as a detergent to permeabilise cell membranes within the tissue to promote lectin binding intracellularly. Then, sections were blocked using 2 % BSA (A7638, Sigma) for 1 h. BSA is a concentrated protein buffer used to compete with lectins for non-specific epitope binding in the sample. High concentrations of protein competitors out-compete lectin binding and reduce background noise during imaging. From this point onwards, darkness was maintained for lectin staining. Eight lectins (SNA-I, MAA, WGA, Con A, UEA-I, WFA, DSA and PNA) (either FITC-conjugated or TRITC-conjugated, EY Laboratories Inc., San Mateo, CA, USA) were prepared in TBS-T and incubated for 1 h with the tissue samples (lectin specificity outlined in Table 2.). These lectins were chosen to investigate various glycosylation motifs common to human cells, including mannosylation, sialylation, galactosylation, fucosylation and GlcNAcylation to capture an overall impression of the glycosignature of these cells. Tissues were washed and counterstained with 1:2,000 0.04 % DAPI, a fluorescent stain that binds to A-T regions of the DNA, thus highlighting the cell nucleus. Slides were washed in TBS-T before coverslip mounting using ProLong® Gold Antifade Mountant (Life Technologies). Imaging was performed within 5 d. All washes were performed 3 times for 5 min each between incubations, unless otherwise stated.

The TBS used was a modified recipe of 20 mmol/L Tris-HCl, 100 mmol/L NaCl, 1 mmol/L CaCl₂, 1 mmol/L MgCl₂, brought to pH 7.2 using concentrated HCl.
Inhibition controls
Haptenic sugar inhibition controls were carried out in parallel during the optimisation phase, according to Table 2. A haptenic sugar is a monosaccharide or disaccharide that can inhibit binding of a lectin. 100 mmol/L solutions of the appropriate sugar in TBS-T were co-incubated with the corresponding lectin for 1 h to verify that the lectin binding was glycan-mediated.

Lectin image analysis and stereology quantification
Quantification was carried out on the foetal samples (n = 3) and degenerated samples (n = 3). Stereology quantification was adopted to calculate the percentage (%) volume fraction of detectable lectin binding in each tissue sample. Lectin histochemical binding fluorescence was obtained from at least 5 microscopic views of each slide with 3 technical and 2 biological replicates using the FIJI/ImageJ software version 1.51 (NIH). Confocal images were converted to binary mode (8 bit) and adjusted to the optimal threshold of positive staining and total area. Volume fraction was calculated by quantifying the area fraction of the positively stained matrix component divided by the total area and converting into a percentage (%) as below:

\[
\text{Percentage volume fraction} = \frac{\text{area fraction} \times 100}{\text{total area}}
\]

Human IVD tissue collection and cell isolation
Ethical approval was sought and obtained from the NUI Galway Research Ethics Committee and Our Lady’s Children’s Hospital, Crumlin Research Ethics Committee for the collection and isolation of IVD cells. Degenerated cells were isolated from patients undergoing discectomy and fusion surgery to treat low-back pain after receiving patient consent (donor age: 36-72 years old; n = 3). Healthy cells were collected from adolescent patients undergoing spinal realignment surgery for AIS with appropriate assent and consent from parents/guardians (donor age: 9-16 years old; n = 3). The authors acknowledge the limitations of using cells isolated from patients with AIS as “healthy” controls; however, they accept their use in the study based on their initial characterisation and phenotype, as presented in the Results section. Furthermore, all healthy cells were isolated from IVD of Pfirrmann grade I on MRI and degenerated cells were isolated from discs with confirmed Pfirrmann grade V (Pfirrmann et al., 2001). IVD tissues were collected from the surgical theatre and sorted at 4 °C until processing for cell isolation within 4 h of procurement from the patient. AF and NP were already separated in the theatre as identified by the surgeon during discectomy. The tissue was weighed based upon an addition to a pre-weighed falcon tube containing PBS (pH 7.4) and 1 % P/S. The sample was centrifuged and supernatant aspirated. Red blood cell lysate was added at this point if tissue appeared bloodstained. After washing, the tissue was minced and a 0.2 % pronase solution (pH 7.4) added for 1 h at 37 °C on a shaker plate at 300 rpm. The tissue was washed twice with PBS and incubated in collagenase solution (100 U/mL collagenase in α-MEM and 10 % FBS) (pH 7.4). The sample was digested overnight and filtered through a 100 µm cell strainer. The cell solution was centrifuged and washed before cell counting. Cells were plated at a density of 10,000 cells/cm². The plate was left untouched for a minimum of 4 d to allow cells to attach to the flask and medium was changed 2-3 times per week after that. Cells were passaged at approximately 70-80 % confluency and all experiments were performed on cells within passage 4 or sooner due to the loss of cell phenotype in 2D culture conditions.

Cytokine-induced inflammation in IVD degeneration
NP cells (3 × 10³) were seeded on a glass surface Ibidi 96-well plate (Fig. 1). Cells were grown in complete medium containing α-MEM, 10 % FBS and 1 % P/S at 37 °C in a humidified atmosphere of 5 % CO₂. After 24 h, cells were stimulated with a cytokine cocktail containing IL-1β, TNF-α and IL-6 at a concentration of 10 ng/mL, which had each previously been shown to induce downstream upregulation of inflammatory markers by qPCR at the given concentration (Gao et al., 2019). The cytokine-containing medium was refreshed every 48 h for up to 10 d. Lectin histochemistry was performed at 24, 72 and 168 h to investigate the effect of cytokine-induced inflammation on glycosylation motif expression in vitro.

Cell viability assay for glycosylation inhibitors
The cytotoxicity of glycosylation inhibitors was investigated by incubating NP cells with each inhibitor. NP cells were plated at a density of 3,000 cells/well in a 96-well plate and treated with varying concentrations of glycosylation inhibitors (Table 1) for 10 d at 37 °C, 5 % CO₂ in a humidified atmosphere. The initial concentrations used for optimisation were based on the manufacturer’s recommendations for a range of efficacy dependent on cell type. Then, cells were washed with PBS and incubated in the dark for 5 h with alamarBlue® assay solution (10 : 1 dilution in complete culture medium). The supernatant was pipetted into a new well plate and absorbance was measured at 540 nm using a plate reader (Varioskan FlashTM, Thermo Fisher Scientific). Measurements were normalised to appropriate controls and blanks. In parallel, cells were similarly seeded and underwent live/dead staining to assess cell survival. Cells were incubated with calcein AM and EthD-1 for 30 min to identify live and dead cells, respectively. Subsequently, cells were fixed and imaged using the Operetta® High Content Imaging System (PerkinElmer).

Reduction in sialylation and fucosylation by Neu5Ac-inhib and Fucose-inhib, respectively, was measured by staining intensity of given lectins. Cells were cultured over 10 d, with medium changes
every 48 h to replenish the inhibitor. After 10 d, cells were fixed for 20 min using 4 % PFA solution. Then, cells were blocked using periodate-treated BSA and stained with FITC-conjugated lectins. Samples were counterstained using DAPI or Hoechst and imaged using the PerkinElmer Operetta® High Content Imaging System. The imaging software was employed to identify each cell nucleus by the DAPI stain and then identify the surrounding cell membrane. The intensity of each membrane staining was calculated using the Harmony software (v3.1.1).

**Cell migration**
Sialylation inhibition was investigated in control and inflammatory cell culture to study its effect on cell migration. Cells were seeded at a density of 20,000 cells/100 µL in each culture insert. Each culture insert, developed for wound healing assays, contained two wells in which cells were allowed to attach, divided by a 500 µm wall. A 500 µm cell-free gap was created until the cells became confluent, after which the insert was removed. The migration of the cells was monitored over 72 h, with images taken every 12 h. The area of gap closure was measured by the area fraction of the cells spanning it. Cell migration of healthy NP cells was compared to that of cytokine-induced cells (IL-1β/IL-6/TNF-α). Cytokine-induced cells were also treated with Neu5Ac-inhib and Fucose-inhib to investigate the role of sialylation and fucosylation in cell migration.

**RNA isolation and gene expression**
RNA isolation and gene expression were performed using a modified protocol based on a previously described method (Mohd Isa et al., 2018). Briefly, cells were washed thoroughly with PBS before 1 mL TRIzol® was added. Scraping was performed using a pipette tip and the TRIzol® solution was transferred to a 2 mL microcentrifuge Eppendorf tube. Samples in TRIzol® were centrifuged at 1,200 ×g for 5 min at 4 °C and the cellular debris was discarded. The clear supernatant was transferred to a clean tube and 200 µL chloroform was added per 1 mL TRIzol® solution, mixed for 15 s and incubated at room temperature for 2 min. The mixture was centrifuged at 4 °C for 15 min and the colourless supernatant that formed on the top of the mixture (containing RNA) was transferred to a new tube. This was mixed with an equal volume of 70 % molecular grade ethyl alcohol. The mixture was transferred to a Qiagen RNeasy Mini column and centrifuged at 16,000 ×g for 15 s; after that, the flow through was discarded. RNA bound to the column was washed with 700 µL of RW1 buffer and 15 s centrifugation at 16,000 ×g. Next, 500 µL of RPE buffer was added to the column, followed by 15 s centrifugation at 16,000 ×g. Then, a further 500 µL of RPE buffer was added and centrifugation was performed for 2 min. RNase-free water (30 µL) was added and the mixture was centrifuged at 16,000 ×g for 1 min to collect RNA in a new collection tube. RNA concentration was determined using a

---

**Fig. 1.** Overview of experimental design of *in vitro* assessment of human NP cells.
Mitochondria function by Seahorse analysis

The Seahorse XFe24 Analyzer (Agilent) was used to continuously monitor OCR and ECAR as per manufacturer’s instructions. 3 d before the experiment, 20,000 cells/well were seeded in an 8-well XFp cell culture plate in α-MEM medium supplemented with 10% foetal bovine serum, 1% P/S and cultivated at 37 °C in a humidified atmosphere and 5% CO₂ with IL-1β/IL-6/TNF-α (10 ng/mL) or Neu5Ac-inhib or a combination of IL-1β/IL-6/TNF-α (10 ng/mL) and Neu5Ac-inhib. At least one well in each assay was used as an internal control. 1 d before the experiment, 1 mL of XF calibrator was added to each well of the XF cartridge and incubated overnight at 37 °C and 0% CO₂ in a humidified atmosphere. 30 min before the experiment, cells were washed with PBS and 625 μL of respective XF assay medium supplemented with 10 mM pyruvate, 1 mM L-glutamine (pH adjusted to 7.4) was added per well and incubated for 30 min at 37 °C and 0% CO₂ in a humidified atmosphere. After 15 min equilibration time, OCR and ECAR were accessed every 8.5 min, 4 consecutive times after the addition of the respective compounds. The different compounds (oligomycin, FCCP, rotenone + antimycin A) were added to the injection ports of the XF cartridge in a 10-fold final concentration and diluted prior the experiment in XF assay medium. Protein concentration was not normalised since a previous investigation (Thompson et al., 1990) demonstrated no effect on cell survival and proliferation rate under these conditions.

Expression of catabolic enzymes by ELISA

Cells were cultured for 72 h with IL-1β/IL-6/TNF-α and co-incubated with either Neu5Ac-inhib or Fucose-inhib. Medium was collected and centrifuged at 2,000 ×g for 10 min to remove debris. Supernatant was removed and total protein collected. Samples were analysed using an MMP-13/ADAMTS-4 ELISA as per the manufacturer’s instructions. The plate was prepared using appropriate lyophilised recombinant protein standards and fluorescence detection based on electrochemiluminescence was performed using the Varioskan Flash™ (Thermo Fisher Scientific) set at an OD of 562 nm using a plate reader.

Statistical analysis

Graphs and figures were created using GraphPad Software. Statistical differences in lectin histochemical quantification were analysed by GraphPad Software. One-way (Kruskal-Wallis) or two-way ANOVA were performed where appropriate followed by Tukey’s post-hoc test. Mean and SEM were calculated for all groups. All error bars indicate SEM.

Results

Altered glycosylation motif expression in degeneration

Lectin histochemical analysis of IVD tissues revealed significant changes in the expression of accessible glycosylation motifs (Fig. 2). Foetal tissues showed the highest intensity of staining. The extracellular structure (lamellar arrangement in the AF) was easily observed, with high cellularity through both tissue types, AF and NP. Con A (binding/selective for α-linked mannose) had little binding specificity for the ECM structures, showing intense staining in the intra/peri-cellular glycome. UEA-1 (binding α-1,2/3 fucose), similarly, lightly stained the ECM (Fig. 2b), while all other lectins (SNA, α-2,6 sialylation; MAA, α-2,3 sialylation; WGA, α-2,3/6 sialylation) produced strong ECM staining throughout all tissue samples (Fig. 2c-e). Thompson grade III/IV (Thompson et al., 1990) tissue showed staining for all lectins. All lectins stained strongly in the ECM structures except Con A (Fig. 2a). The structure of the AF appeared completely disorganised with decreased cellularity. The NP also had decreased cellularity and granulomatous type structures were observed in the tissue. A granular pattern of staining was observed for Con A.

Oligo-mannose

Con A had little binding specificity for the ECM structures in foetal tissue, showing strong staining in the intra/peri-cellular glycome, while in diseased tissue grade III and IV there was a higher intensity of uniform ECM staining in the AF, with granular patterns also observed in both AF and NP (Fig. 2a). The volume fraction of positive staining in the NP and AF tissue was larger in degeneration and distribution of staining was visibly changed. This correlated with the altered oligomannose expression characterised by UPLC-MS. Con A lectin binds to oligomannose glycans and an increase in the expression of...
oligomannose structures is typically regarded as a progenitor cell marker (Hamouda et al., 2013).

**Sialylation**

**MAA**

High intensity staining with MAA was observed uniformly across the ECM in both AF and NP, with a sharp demarcation observed in the NP (Fig. 2d). The degenerated samples stained differently from the foetal tissue due to altered morphology: the ECM of the AF was disorganised, showed sharp demarcations and appeared more friable than foetal AF. The NP presented a granulomatous cluster of cells and granular staining in the ECM with strong peri-cellular staining. There was more binding of MAA in the NP of degenerated tissue when compared to healthy foetal tissue. This was consistent with a study by Mohd Isa et al. (2018) correlating an increase in sialylation with tissue inflammation.

**WGA**

Very high intensity staining was observed with WGA (Fig. 2e). The positive staining was restricted to the AF fibres, which reflected the lamellar arrangement of the tissue. Degenerated tissue had an intense AF staining, demonstrating a disorganised pattern of ECM structures. The NP was stained weakly, with a possible granulomatous structure observed.

---

Fig. 2. The glycosignatures of healthy foetal and degenerated adult IVD tissue were different. (a) Mannosylation, (b) fucosylation and (c-e) sialylation motif expression in healthy foetal tissue and degenerated adult tissue using lectin histochemistry. Graphs indicate a change in the % volume fraction of lectin binding sites in degeneration relative to healthy IVD. Confocal images of mannose were detected by Con A, α-(1-2/3)-fucosylation by UEA-I and α-(2,6)-linked sialic acid, α-(2,3) sialylated galactose, N-acetylglucosamine and sialic acid by SNA, MAA and WGA, respectively. (f) Mannosylation and (g) fucosylation trended towards a decrease in expression. (h) α-(2,6)-linked sialylation was increased in degenerated tissues while total sialylation trended towards an increase. Two-way ANOVA with Tukey’s post-hoc test, data presented as mean ± SEM. Scale bar: 50 µm.
SNA
Staining for SNA-binding sites in the AF of the foetus reflected the lamellar arrangement of the tissue (Fig. 2c). SNA staining in the foetal NP demonstrated a high intensity peri-cellular pattern, with low intensity staining throughout the ECM. Degenerated tissue showed high intensity staining of the ECM in the AF, although a lamellar formation was not observed. Low cellularity and deranged staining pattern were apparent. The AF and NP were highly stained, more than foetal samples, in the degenerated tissues, where higher levels of sialylation were observed. This was in line with a previous demonstration of high levels of sialylation in inflamed or degenerated human chondrocytes (Pabst et al., 2010; Toegel et al., 2013).

Glycosignature of NP cells
The glycosignatures of healthy and degenerated NP cells were characterised by various lectins specific for a spectrum of glycosylation motifs (Fig. 3a). SNA (α-2,6 sialylation), AAL (α-1,6 fucosylation) and GS-I-B4 (β-1,4 galactosylation) were all significantly increased in degenerated cells, while binding capacity of MAA (α-2,3 sialylation), UEA-I (α-1,2/3 fucosylation) and Con A (α-1,6 mannosylation) was significantly decreased \( (p < 0.05) \). Lectin specificity and preferential binding to glycosylation motifs are based upon motif of highest affinity, as described in the literature (Haab, 2012; Haab and Klamer, 2020).

Cell viability and inhibition of global fucosylation and sialylation
The stability of glycosylation motif expression in NP cells across passaging and expansion was investigated up to passage 7 (Fig. 3c,d). The binding intensity of SNA, AAL and Con A did not change significantly across passaging. NP cells are generally considered to lose their phenotype after passage 6 and are only used experimentally within these limits (Richardson et al., 2017).

NP cells incubated with specific global inhibitors of glycosylation, Neu5Ac-inhib and Fucose-inhib, underwent analysis for metabolic activity and overall cell survival. There was no significant change in the metabolic activity as detected by the fluorimetric readout of alamarBlue® assay (Fig. 5a) nor was there a decrease in cell survival when NP cells were incubated with varying concentrations of inhibitor for 10 d (Fig. 5b).

After 10 d, these cells underwent lectin histochemical analysis to determine the efficacy of inhibition. Sialylation decreased by 43.55% \( (p < 0.001) \).

Fig. 3. Both degenerated and inflamed NP cells expressed similar glycosignatures characterised by increased sialylation and fucosylation as well as decreased mannosylation. (a) Altered glycosignature of human NP cells isolated from healthy and degenerated IVDs. Lectin histochemical characterisation revealed increased binding of SNA, AAL and Con A in degenerated NP cells that were specific for sialylation, fucosylation and mannosylation, respectively \( (p < 0.05) \). (b) Glycosignature of human healthy NP cells induced with inflammatory cytokines. The altered binding specificity of SNA and AAL was increased on day 3 in the cytokine-treated group. (c,d) Stability of glycosylation motif expression in human NP cells through passaging. There was no significant difference detected in sialylation, fucosylation and mannosylation from passage 1 (p1) to passage 7 (p7) as detected by SNA, AAL and Con A, respectively. \( n = 3 \). Scale bar: 50 µm. Two-way ANOVA with Tukey’s post-hoc test, data presented as mean ± SEM.
as shown by SNA staining, where no change was observed for MAA staining (Fig. 5c,d). No further inhibition of sialylation was observed with inhibitor concentration higher than 300 µmol/L (Fig. 5g). Fig. 5c depicts the confocal images of NP cells with and without Neu5Ac-inhib after 10 d, where no change in cellular morphology was observed. No specific pattern of sialylation was altered; however, there was a global decrease in SNA-binding ($p < 0.001$).

A similar trend was observed with the Fucose-inhib, with a decrease in core fucosylation, detected by AAL, of 73.37% ($p < 0.001$) (Fig. 5f). The most significant decrease was observed at 300 µmol/L of inhibitor, which did not decrease further with higher concentrations of Fucose-inhib (Fig. 5h). This was in contrast with UEA-I binding, which detected no significant change across inhibitor concentrations. Fig. 5e demonstrates the change in AAL and UEA-I binding in cells inhibited with Fucose-inhib. The confocal images showed an apparent change in cell morphology towards a more elongated phenotype in inhibitor-treated cells. UEA-I lectin binding pattern was also altered, with focal streaky intensity observed. However, overall UEA-I intensity was unchanged.

Optimisation of in vitro inflammatory model of NP cells

Initially, the glycosylation profile of NP cells was investigated when stimulated with individual cytokines (Fig. 4). IL-1β had the most prominent effect after 3 d, increasing sialylation (measured by

---

**Fig. 4.** Cytokine-mediated inflammation induced hyperglycosylation in NP cells. (a) Sialylation response to cytokine-induced inflammation measured by MAA and SNA binding. (c) IL-1β had the most prominent effect after 3 d, increasing sialylation by 62%, whereas TNF-α and IL-6 increased sialylation by 56% and 19%, respectively. The cytokine combination increased sialylation by 89%. (b) Fucosylation response to cytokine-induced inflammation measured by AAL and UEA-I binding. (d) IL-1β induced the largest fucosylation response of all the cytokines (35% increase) followed by TNF-α and IL-6, 11% and 6% increases, respectively. A combination of cytokines caused a 46% increase in core fucosylation. $n = 3$. Scale bar: 50 µm. One-way ANOVA with Tukey’s post-hoc test, data presented as mean ± SEM.
SNA) by 62.86 % ($p < 0.001$), whereas TNF-α and IL-6 increased sialylation by 56.41 % ($p < 0.001$) and 18.90 % ($p = 0.1999$), respectively (Fig. 4a,c). The greatest response, as measured by SNA-binding, was observed with a combination of all cytokines, with a significant total increase in sialylation expression, as detected by SNA, of 89.11 % ($p < 0.001$). MAA binding expression demonstrated marginally increased staining with TNF-α and cytokine combination, despite not being statistically significant ($p = 0.1816$).

Similar results were observed measuring fucosylation expression under cytokine stimulation, as a hyperfucosylated state emerged (Fig. 4d). IL-1β caused the most significant hyperfucosylation response (measured by AAL) of all individual cytokines (35.03 % increase, $p < 0.01$) followed by TNF-α and IL-6, 11.44 % ($p = 0.7574$) and 6.46 % ($p = 0.9616$), respectively. A combination of cytokines caused a 46.45 % increase in core fucosylation, indicating an additive effect ($p < 0.0001$). No trend in fucosylation modulation was observed with UEA-I binding. This cytokine combination was used in all further investigations as it reliably reproduced the hypersialylated and hyperfucosylated glycophenotype observed in degenerated cells and tissues.

The glycosylation motifs of NP cells when stimulated with a cytokine mix were examined by lectin cytochemistry (Fig. 3b). The most prominent alteration in the glycosylation pattern was observed on day 3 vs. day 1 and 7. There was a significant increase in binding of SNA (45.57 %, $p < 0.01$), AAL (43.12 %, $p < 0.05$) and Con A (35.76 %, $p < 0.05$) on day 3. The binding pattern of lectins on day 3 best reflected the glycosylation pattern of degenerated NP cells, both demonstrating increased α-(2,6) sialylation and α-(1,6) fucosylation detected by SNA and AAL, respectively.

Fig. 5. Small molecule glycosylation inhibitors were non-cytotoxic and efficient inhibitors of sialylation and fucosylation. Viability study of NP cells after treatment with varying concentrations of 3Fax-Peracetyl Neu5Ac and 2F-Peracetyl-Fucose. (a) There was no significant difference observed in metabolic activity across all groups as measured by alamarBlue™ assay. (b) Live/dead assay determined total cell survival after treatment. All concentrations of inhibitor maintained > 95 % cell survival after 10 d co-incubation with no significant difference across groups. (c,d) Optimised inhibition of sialylation in NP cells by 3Fax-Peracetyl Neu5Ac. Confocal images showed no change in cell morphology in treatment vs. control. α-(2,6) sialylation (SNA) was significantly decreased ($p < 0.001$) by ~ 40 % while α-(2,3) sialylation (MAA) expression remained unaltered. (e,f) Optimised inhibition of fucosylation in NP cells by 2F-Peracetyl-Fucose demonstrated no change in cell morphology in treatment vs. control. α-(1,6) fucosylation (AAL) was significantly decreased ($p < 0.001$) by ~ 70 % while α-(1,3) fucosylation (UEA-I) remained unaltered. (g,h) Expression of glycosylation modifications after treatment with global inhibitors of glycosylation. Sialylation fluorescence intensity as detected by MAA-α-(2,3) and SNA-α-(2,6) lectins. α-(2,6) sialylation was reduced significantly by ~ 40 % at a concentration of 300 µmol/L of 3Fax-Peracetyl Neu5Ac after 10 d of treatment. Core fucosylation α-(1,6) expression as measured by AAL decreased with increased concentration of 2F-Peracetyl-Fucose to ~ 70 % reduction at 300 µmol/L of inhibitor. $n = 3$. One-way ANOVA with Tukey’s post-hoc test, data presented as mean ± SEM.
Expression of ECM proteins in healthy and degenerated NP cells was characterised by qPCR (Fig. 7a). COL1 expression was the same in both healthy and degenerated cells, while COL2 and ACAN expression were reduced of 99.78 % (p < 0.001) and 67.54 % (p < 0.01), respectively, in degenerated NP cells. Expression of all measured ECM components (COL1, COL2, ACAN) was reduced in healthy cells induced with cytokines for 3 d (p < 0.05). COL1 expression was diminished in degenerated cells under cytokine stimulation (p < 0.05); however, no noticeable reduction was recorded in the already reduced COL2 and ACAN expression.

**Glycosylation inhibitors effectively regulated sialylation and fucosylation in an in vitro model of inflammation**

The glycomic response of NP cells was measured with respect to inflammation in both healthy and degenerated human NP cells (Fig. 6). The baseline sialylation of degenerated NP cells was more significant than healthy NP cells, as previously characterised (p < 0.01). A cytokine cocktail increased sialylation in both healthy and degenerated cells of 80.40 % and 10.07 %, respectively. This increase was consequently inhibited by Neu5Ac-inhib, retaining the sialylation motif expression at healthy baseline levels in healthy cells, 5.54 % difference vs. baseline (p = 0.9987), 41.49 % decrease vs. cytokine stimulation (p < 0.0001) (Fig. 6a,c). In degenerated cells treated with Neu5Ac-inhib, the sialylation expression was further reduced to the baseline of healthy NP cells, 18.54 % reduction vs. baseline (p = 0.18) and 23.00 % reduction vs. cytokine stimulation (p < 0.05).

Inhibition of hyperfucosylation in cytokine-induced inflammation treated with Fucose-inhib was assessed by AAL staining (Fig. 6b,d). Initial baseline fucosylation in degenerated NP cells was lower than healthy NP cells (p < 0.05). Binding of AAL was increased in the IL-1β/IL-6/TNF-α group after 72 h (p < 0.001). This hyperfucosylation response was inhibited by Fucose-inhib in both degenerated and healthy NP cells (p < 0.001).

**Glycosylation inhibitors downregulated collagen expression**

COL1 and COL2 expression was measured by qPCR, where mRNA was extracted from healthy and inflamed NP cells with or without glycosylation inhibitors after 3 d of cytokine/inhibitor stimulation. Fig. 7b,d indicates the initial expression of COL1/2 in NP cells normalised to 18S ribosomal subunit. Cytokine stimulation reduced COL2 significantly (p < 0.01). Neu5Ac-inhib enhanced COL2 expression (p < 0.01), while Fucose-inhib had no effect. Neu5Ac-inhib had no effect on modulation of collagen expression in cytokine stimulation; however, Fucose-inhib further reduced COL1 and COL2 expression in cytokine stimulation (p < 0.001). While Neu5Ac-inhib did not influence total collagen RNA expression, the COL2 : COL1 ratio, an important marker of NP cell phenotype (Clouet et al., 2009), was maintained under cytokine-induced inflammation (Fig. 7e). Fucose-inhib had no effect on COL2 expression and further diminished the COL2 : COL1 ratio (Fig. 7e).

**Fig. 6. Small-molecule inhibitors of glycosylation inhibited cytokine-mediated hyperglycosylation.** (a) Sialylation response to cytokine-induced inflammation measured by MAA and SNA binding. (c) IL-1β had the most prominent effect after 3 d, increasing sialylation by 62 %, whereas TNF-α and IL-6 increased sialylation by 56 % and 19 %, respectively. Cytokine combination increased sialylation by 89 %. (b) Fucosylation response to cytokine-induced inflammation measured by AAL and UEA-I binding. (d) IL-1β produced the largest fucosylation response of all the cytokines (35 % increase) followed by TNF-α and IL-6, 11 % and 6 % increases, respectively. A combination of cytokines caused a 46 % increase in core fucosylation. n = 3. Scale bar: 50 µm. One-way ANOVA with Tukey’s post-hoc test, data presented as mean ± SEM.

K Joyce et al.  The role of glycosylation in IVD degeneration

www.ecmjournal.org
MMP-13 synthesis was inhibited by glycosylation inhibition
MMP-13 and ADAMTS-4, potent collagenase/aggrecanase degrading enzymes (Fearing et al., 2018), were upregulated in cytokine-stimulated NP cells, as measured by ELISA normalised to protein expression ($p < 0.01$) (Fig. 8). The release of MMP-13 and ADAMTS-4 was inhibited by Neu5Ac-inhib ($p < 0.01$) and tended to decrease with Fucose-inhib co-incubation ($p = 0.07, p = 0.11$, respectively).

Cell migration modulation
Cell migration assays demonstrated the reduced mobility of inflamed NP cells. The calcein AM staining of live cells allowed for enhanced visualisation of NP cells in this gap closure assay (Fig. 9). At the 48 h time point, there were clear and significant differences across experimental groups. Neu5Ac-inhib restored the migration of inflamed NP cells (no migration observed) to within normal limits ($10.26 \pm 2.12 \%$ closure, $p = 0.08$) and further increased baseline migration in non-inflamed cells ($25.23 \pm 2.91 \%$ closure vs. $18.00 \pm 1.47 \%$ closure, $p = 0.10$) (Fig. 9a,c).

Fucose-inhib reduced cell migration across both inflamed and non-inflamed cells (Fig. 9b,d). This time point was recorded at 72 h as opposed to 48 h in which the previous assay was recorded. This disparity was used to illustrate the difference between inflamed cells and inflamed cells treated with Fucose-inhib, since no migration was observed at 48 h. After 72 h, $71.02 \pm 0.55 \%$ gap closure occurred in the control group, while this was reduced in inflamed cells ($53.98 \pm 1.24 \%$, $p < 0.0001$). When treated with Fucose-inhib, cell migration decreased in both control ($71.02 \pm 0.55 \%$ vs. $59.86 \pm 1.23 \%$, $p < 0.001$) and cytokine stimulation ($53.98 \pm 1.24 \%$ vs. $42.95 \pm 0.60 \%$, $p < 0.001$) groups.

Fig. 7. COL and ACAN expression was modulated by inflammatory signalling and glycosylation pathways. (a) Expression of ECM proteins in healthy and degenerated NP cells. COL1 expression was the same in both cell types while COL2 and ACAN were reduced in degenerated NP cells. Expression of all ECM proteins was reduced in cells induced with cytokines after 3 d. (b) 3Fax-Peracetyl Neu5Ac treatment increased COL2 expression in non-inflamed cells ($p < 0.01$). No significant difference was seen in inflamed groups. (c) The ratio of COL2 : COL1 expression, a marker of NP cell phenotype, was maintained in 3Fax-Peracetyl-treated cells, although total gene expression was decreased. (d) 2F-Peracetyl-Fucose had no effect on healthy NP cells and further reduced COL2 expression in inflamed NP cells. (e) COL2 : COL1 ratio was further lost in 2F-Peracetyl-Fucose-treated inflamed cells. Two-way ANOVA with Tukey’s post-hoc test, data presented as mean ± SEM.
Mitochondrial dysfunction in inflammation

The effect of sialylation inhibition on inflamed NP cells was investigated by the Agilent Seahorse XFe24 Analyzer using the Mito Stress test® (Fig. 10). Mitochondrial physiology was investigated by measuring ECAR and OCR, critical indicators of mitochondrial function and respiratory capacity. NP cells showed a low basal mitochondrial oxygen consumption that was approximately 50% coupled to ATP production. Treatment with cytokine stimulation induced a significant increase in basal and maximal OCR (FCCP-treated, a potent uncoupler of mitochondrial oxidative phosphorylation) (p < 0.001) (Fig. 10a). The increase in basal and maximal OCR was inhibited by Neu5Ac-inhib (p < 0.001) (Fig. 10c). The residual OCR after oligomycin treatment indicated no difference in proton leak across groups. Altogether, these results indicated that the activation of the inflammatory pathways regulated mitochondrial respiratory function, altering glycolysis, ECAR and OCR in a glycosylation-dependent manner.

Discussion

The results of the initial lectin histochemical analysis were consistent with a previous glycosylation profiling in an injury rat-IVD model where higher levels of sialylation in injured discs were observed (Mohd Isa et al., 2018). Mohd Isa et al. (2018) showed that surgically induced IVD injury is associated with altered glyco-profile and degenerative changes in the disc, including neurotransmission, inflammation as well as an imbalance of catabolism and anabolism. The results of the rat-tail model study may also be validated by an ovine animal model of degeneration, showing similar findings as to glycosylation changes in aged degeneration (Collin et al., 2016). The study reported that specific spatial and temporal glycans patterns throughout maturity were observed and specific glyco-markers were identified, which allowed distinction between NP and AF tissues and cells. The present study showed similar trends in lectin binding in inflammation to the IVD model created from bovine tissue, demonstrating increases in sialylation, mannosylation and galactosylation when cells were stimulated with IL-1β (Srivastava et al., 2017).

The initial characterisation of human NP cells in situ in healthy and degenerated IVD tissues and after isolation revealed a previously characterised phenomenon of hypersialylation and hyper-fucosylation in IVD tissues in inflammation and degeneration (Kazezian et al., 2017; Mohd Isa et al., 2018). The present was the first glycosignature obtained from human NP cells in the literature. The increased positive staining of SNA and AAL found in the present study indicated an increase in α-(2,6) sialylation and core fucosylation. These signatures were previously reported to be upregulated in chondrocytes and epithelial cells in response to inflammatory cytokines (Delmotte et al., 2002; Pabst et al., 2010). Cytokine-induced healthy NP cells produced a similar glycosylation profile to degenerated NP cells, characterised by increased SNA, WGA and AAL positive staining. The replication of this glycosignature gives further validation to the in vitro inflammatory model in relation to the glycomic response of NP cells in degeneration. The downstream regulation of glyco-enzymes and post-translational modifications during protein synthesis and trafficking is highly complex, reflected by the varying responses to IL-1β, IL-6 and TNF-α.

The NP phenotype is gradually lost through passaging and cells generally lose key markers beyond passage 5 (Benya et al., 1978; van den Akker et al., 2014). Therefore, it was crucial to consider the
stability of the glyco-phenotype of the NP cell through passaging and expansion. The glycosignature remained stable through to passage 7, indicating that glyco-enzyme activity was highly conserved through cell proliferation under stable conditions.

Small-molecule-inhibitors are very useful in biomedical applications for biomaterial functionalisation due to their relative stability and ease of delivery (Natoni et al., 2020). Neu5Ac-inhib and Fucose-inhib were investigated for their potential to modulate the glycome in vitro. It was initially confirmed that these molecules did not have a detrimental effect on cell metabolism and viability. The efficacy of inhibition was determined for each molecule and the most significant inhibition was achieved at 300 mmol/L as per the manufacturer’s instructions. No specific pattern of sialylation was altered; however, there was a global decrease in SNA-binding positivity \((p < 0.001)\), whereas no change in MAA binding was observed. This indicated an increased turnover and subsequent preferential inhibition in primarily α-(2,6) sialylation over α-(2,3) sialylation. The mean expression of fluorescence intensity of SNA was also much more significant than that of MAA, indicating a larger proportion of accessible α-(2,6) sialylation to α-(2,3) sialylation overall, assuming similar binding efficiencies and specificity of lectins.

Similar trends were seen in fucosylation inhibition, where AAL binding was significantly reduced after inhibition vs. UEA-I binding, which was unaffected. The change in UEA-I binding was indicative of ER stress, with bottlenecks in glycan synthesis due to the inhibition of core fucosylation, a crucial glycan modification for the activity of many proteins. However, this phenomenon needs further investigation.

Collagen is a glyco-modified protein whose degradation is altered by the level of glycosylation (Jürgensen et al., 2011). Therefore, synthesis and trafficking of collagen are influenced by glycosylation efficiency in the GA. The effect of cell glycosylation on collagen synthesis was investigated by PCR. It appears that sialylation inhibition promoted COL2 synthesis. However, this effect has not previously been investigated and the mechanism by which this process may be regulated is unknown. The prominent factor in this investigation was that Neu5Ac-inhib retained the NP cell phenotype in inflammation. However, sialylation inhibition was not sufficient...
to sustain overall COL1 and COL2 expression at a transcription level.

The monosaccharide synthesis pathways that are glycan precursors are intrinsically linked to metabolism (Ryczko et al., 2016). Also, the inflammatory cascade increases mitochondrial activity and dysfunction (López-Armada et al., 2013). The gain of TGF-β function demonstrated that when an epithelial (low TGF-β production) cell line is chronically incubated with TGF-β, significant decreases in OCR are observed at all levels: basal, ATP-linked and maximal. Cytokine-induced inflammation caused an increase in maximal OCR, as well as in the percentage of OCR dedicated to ATP synthesis. Neu5Ac-inhib decreased the respiratory capacity of the mitochondria, possibly through a negative feedback loop through an increase in ManNAc. However, this mechanism warrants further investigation.

Glycosylation is a crucial modification for final protein assembly, vesicle packing and trafficking to the cell membrane. Inhibition of this process is likely to reduce protein translation in the ER. MMPs, ADAMTSs and their regulators, TIMPs, are affected by the degree of glycosylation to modulate expression and function. For example, MMP-3 has been shown to accumulate in rheumatoid arthritis with increased expression of O-GlcNAc (Takeshita et al., 2016). Cleavage of outer arm fucose residues from the N-glycans of TIMP-1 or knockdown of both FUT4 and FUT7 enhanced the MMP-binding and efficacy of TIMP-1 (Kim et al., 2013). MMP-13 expression was reduced by both Neu5Ac-inhib and Fucose-inhib, indicating that it was possible to diminish the inflammatory response mounted by the cell through reduced protein synthesis. Glycosylation inhibitors inhibit the trafficking of proteins through the GA due to hypoglycosylation and ER stress (Blackburn et al., 2018). However, this reduction in protein synthesis is non-specific and is likely to have undesired reductions in the synthesis of critical regulatory proteins. While studies have shown that MMP activity may be altered depending on the occupation of glycosylation sites and terminal glycosylated motifs on the enzyme (Boon et al., 2016), the activity of MMPs was not measured in the present study. The reduction in MMP secretion suggested either global inhibition of protein synthesis, non-specific to proteases or inhibition of inflammatory signalling to induce upregulation of catabolic enzymes. It is likely due to a combination of both processes.

CD44 N-linked glycosylation plays a significant role in cell attachment and migration (Rodgers et al., 2011; Sackstein et al., 2008). Inhibition of fucosylation diminishes sialyl-Lewis X/A motif and, thus, reduces E-selectin ligand expression. α-(1,3) fucosyltransferase upregulation can induce potent E-selectin binding (Sackstein et al., 2008). Sialylation is involved in cellular mechanisms that govern attachment and migration. It was previously shown that upregulated ST6Gal1 expression strongly inhibits monocyte-transendothelial migration through

---

**Fig. 10.** Mitochondrial dysfunction in NP cell inflammation was ameliorated by sialylation inhibition. Seahorse analysis of mitochondrial respiratory capacity in NP cells in a model of inflammation. Cells were incubated 30 min prior experiment in XF assay medium supplemented with 5 mmol/L glucose and 2 mmol/L glutamine and subsequently injected with oligomycin (1 μmol/L), FCCP (1.5 μmol/L), antimycin (1 μmol/L) and rotenone (1 μmol/L). (a) Continuous OCR values (mpH/min) and (b) ECAR values (pmoles/min) are shown. (d) The percentage of ATP-linked OCR was calculated as ATP-linked OCR/basal OCR. * p < 0.05, ** p < 0.01, *** p < 0.001. n = 3. One-way ANOVA. Data presented as mean ± SEM.
sialylation of β-catenin (Zhang et al., 2018), while ST6Gal1-mediated sialylation also promotes integrin β1 function in adhesion and migration of colonic cancer cells (Lee et al., 2010) and CHO cells (Shi et al., 2017). An increase in cell migration is observed in desialylated endometrial stromal cells after neuraminidases activity (Maingien et al., 2019), where desialylation is measured using SNA, an α-(2,6) sialic acid-binding lectin. The disparity in the contradictory role of sialylation in migration, especially in cancer cell lines, can be attributed to the upregulation of β-galactoside α-(2,6) sialyltransferase 1 (Lu et al., 2016). The increased cell migration after sialylation inhibition observed in vitro in NP cells in the present study may be attributed to the net positive charge on the cell surface. The net positive charge created an electrostatic attraction with the negatively charged tissue culture plastic, driving cell migration. This would be a favourable cell surface modification for cell integration into a negatively charged biomaterial such as a hyaluronic acid hydrogel.

The role of fucosylation in cell migration may be explained much more simply. Defucosylation inhibits cell migration, whereas FUT8 deficiency suppresses cell migration by impacting the core fucosylation of E-cadherin and the downstream FAK/integrin pathway (Chen et al., 2013: Isaji et al., 2006; Liu et al., 2020). Reversely, upregulated fucosylation through FUT1,2,3,6 and 8 increases cell migration and is associated with poor prognosis in non-small cell lung cancer (Park et al., 2020) and hepatoma (Wu and Chen, 2009). This inhibition is not favourable as a cell surface modification as the primary effect is core fucose inhibition and decreased cell migration. While outer arm fucosylation is aberrantly expressed in NP cells in degeneration, amelioration through global inhibition causes detrimental loss of core fucosylation.

Conclusions

The glycosignature of the NP cells in healthy and diseased tissues has been characterised and a validated inflammatory model of IVD degeneration has been developed. Small-molecule fluorinated sugar analogues (3Fax-Peracetyl Neu5Ac; 2F-Peracetyl-Fucose) were used to inhibit sialylation and fucosylation in an in vitro model of inflammation, to investigate their effects on glycosignature, cell metabolism, ECM synthesis and cell migration. In the in vitro model of IVD degeneration, cytokine-induced inflammation induced hypersialylation and hyperfucosylation in human NP cells. However, this modification was inhibited by Neu5Ac-inhib and Fucose-inhib, respectively. Inhibition of sialylation and fucosylation modulated cell migration and protein translation of catabolic enzymes in response to inflammation. Small-molecule inhibitors of glycosylation appeared to have a profound effect on cell secretome, influencing protein synthesis, matrix deposition and cell surface glycosylation. Neu5Ac-inhib retained the NP cell glyco-phenotype in inflammation, diminished catabolic enzyme release and increased cell motility. However, Fucose-inhib had deleterious effects on cell migration and ECM synthesis. When introducing a biomaterial into the IVD, tissue integration and material resorption are essential parameters that can be influenced by modulation of sialylated motifs. Neu5Ac-inhib may have a potentially beneficial therapeutic effect delivered by a carrier system in treating IVD degeneration. The role of sialylation and fucosylation have been investigated in the NP cell in an in vitro model of IVD degeneration and potential glycomic-based mechanisms of degeneration and disease targets have been identified.

Acknowledgements

The authors sincerely thank Mr Patrick Kiely and staff, Our Lady’s Children’s Hospital, Crumlin for providing IVD tissue, Emer Bonham at UCD Conway for access to tissue processing facilities and Joao Marques Garcia at Utrecht University for the collection and preparation of the IVD material. This publication is the result of research conducted with the financial support of the College of Medicine, Nursing and Health Sciences, NUI Galway/Science Foundation Ireland (SFI) and the European Regional Development Fund (Grant Number 13/RC/2073). The authors acknowledge the facilities and scientific and technical assistance of the Centre for Microscopy and Imaging, Genomics and Screening Core, a facility that is funded by NUI Galway and the Irish Government’s Programme for Research in Third Level Institutions, Cycles 4 and 5, National Development Plan 2007-2013. The authors declare no conflict of interest.

References


The role of glycosylation in IVD degeneration


This page has been referenced from "The role of glycosylation in IVD degeneration" by K Joyce et al., Proc Natl Acad Sci U S A 108: 11332-11337.
K Joyce et al.                                                                                                    The role of glycosylation in IVD degeneration


**Discussion with Reviewers**

**Catarina Leite Pereira**: This study used cells from different donors. Diseased donors have a larger age range. Did the authors find out any correlation with age in the observed results? If data were aggregated by age groups, would this have an influence on the glyco-pattern? What about the degenerative levels? Can the glycome correlate with Pfirrmann grades and be used as an indicator of disease progression?

**Authors**: This is a very interesting question and something we have considered during the study. An initial screening was performed across nine donors of degenerated IVD tissue and a regressional analysis was performed based on age and grade of disease; however, no differences were observed across donors. This may be due to small sample size but also to the necessity of passing cells before analysis, which may occlude sensitive motif changes in the glycosignature. We would anticipate that a high-powered study using techniques such as lectin microarray and principal component analysis may discern age- and grade-dependent motifs.

**Catarina Leite Pereira**: How do the authors envisage the application of the glycome as a target for IVD disease progression? Which novel therapies can arise from the full characterisation of IVD “glyco-pattern”?

**Authors**: Glyco-functionalisation of implantable biomaterials would be the next intuitive step in this line of investigation. There are multiple approaches available to promote and inhibit specific glycosylation changes to modulate the glycome towards a healthy and regenerative glyco-phenotype. It is unlikely that glycome-based targets are sufficient to halt degeneration and restore normal disc function alone; however, glyco-functionalised materials may improve cell migration, cell-material interaction, downstream signalling, protein synthesis and trafficking towards efficacious material responses.

**Reviewer 2**: The *in vitro* model developed in the present work was in 2D. While the authors did evaluate maintenance of NP phenotype in 2D conditions, do they envisage differing outcomes, such as the effects of the inhibitors, if the NP cells were in 3D?

**Authors**: The effect of sialylation inhibition on cell survival and proliferation was briefly investigated in a 3D cell culture medium but no differences versus controls were observed. However, it would be interesting to investigate the cell-material interactions in 3D cultures using biomaterial-based structures, such as collagen scaffolds, since integrin- and selectin-mediated cell-matrix interactions are tightly regulated by protein glycosylation, specifically sialylation and fucosylation through sialyl-Lewis-X motifs.

**Reviewer 2**: How do the authors envision these inhibitors being applied clinically: at which stage of degeneration would they most likely be applied, how would they be applied? Have the authors anticipated unwanted side effects from the molecules besides the intended target?

**Authors**: In IVD degeneration, these small-molecule inhibitors can be loaded into injectable hydrogel formulations for local delivery into the disc, with the potential to promote cell migration into the material, modulate cell metabolism and inhibit pro-inflammatory pathways. We anticipate this approach to be most efficacious in early degeneration while native cell populations remain high. Sialylation inhibition is already gaining popularity in other fields, such as oncology, as sialylation plays a crucial role in cell migration and metastatic disease. Such applications require systemic delivery of the drug known to be highly nephrotoxic, necessitating targeted delivery. However, in the case of IVD degeneration, local drug delivery on a carrier into an avascular space is highly unlikely to be released into systemic circulation at a high enough concentration to cause kidney injury.

---

**Editor’s note**: The Guest Editor responsible for this paper was Andrea Vernengo.